A dermatological protocol pairing two synergistic peptides to address the two primary mechanisms of visible skin aging: chronic inflammation and dermal matrix breakdown. KPV calms the inflammatory cascade at the nuclear level; GHK-Cu rebuilds the structural matrix. The result is measurable improvement in clarity, density, and tone. For patients who have come across pre-compounded dermal-repair blends - KPV layered onto a GHK-Cu / BPC-157 / TB-500 base, sold direct-to-consumer in the medspa market - V-06 is the supervised clinical version: the same anti-inflammatory + matrix-synthesis logic, scoped to the dermatological indication, allocated and monitored within a physician workflow.

A regenerative protocol for patients managing chronic tendinopathy, post-surgical recovery, or refractory inflammatory conditions. Three synergistic peptides target distinct phases of tissue repair - vascular scaffolding, cellular proliferation, and matrix reorganization - to restore structural integrity that monotherapy cannot achieve alone. For patients who have come across pre-compounded tissue-repair blends in the market (combinations of BPC-157, TB-500 and GHK-Cu sold direct-to-consumer), V-01 is the physician-supervised, biomarker-monitored equivalent - the same regenerative building blocks, allocated and monitored within a clinical workflow rather than self-administered from a vial.

A metabolic protocol for patients pursuing significant weight reduction while preserving lean mass and dermal architecture. Combines incretin-driven fat loss with growth-hormone secretagogue activity to address what monotherapy GLP-1 protocols often produce: facial volumetric loss, dermal sagging, and accelerated skin laxity. BPC-157 is available as a physician-evaluated adjunct for patients sensitive to GI side effects during titration.

A next-generation metabolic protocol built around Retatrutide, an investigational triple agonist of GLP-1, GIP, and glucagon receptors. Designed for patients with refractory metabolic dysfunction who have plateaued on dual-agonist therapy, or who require the additional glucagon-pathway thermogenic effect. Patient selection is rigorous - this protocol is allocated only after physician review of metabolic history and contraindication screening. BPC-157 is available as a physician-evaluated adjunct for GI tolerability support during titration.

A conservative two-compound protocol for patients pursuing physician-supervised optimization of the growth hormone axis. Pairs a GHRH analogue with a selective ghrelin-receptor agonist to amplify the body's own pulsatile GH release - without exogenous GH administration. The protocol is administered as a daily subcutaneous injection, typically pre-sleep on an empty stomach, to align with the body's natural overnight GH pulse. Used for body-composition support, recovery from training load, and IGF-1 trend management in healthy adults under clinical supervision.